Overview


According to FutureWise analysis the market for allergic conjunctivitis drug is expected to reach US$ 6.15 billion by 2031 at a CAGR of 6.12%.

Allergic conjunctivitis (AC) is a frequent disorder caused by allergens such as animal dander, pollen, or mold. It is primarily mediated by allergen-induced crosslinking of immunoglobulin E on receptors on primed conjunctival mast cells, resulting in mast cell degranulation, histamine release, and the release of lipid mediators, cytokines, and chemokines. The clinical manifestations are conjunctival hyperaemia, tearing, acute itching, and chemosis. Refractory and chronic cases might lead to ocular surface problems that can impair vision. Patients with even minor manifestations of this condition have a negative impact on their quality of life. Non-pharmacologic therapy, as well as ocular and systemic approaches, are currently available. However, numerous treatments are frequently necessary to adequately regulate AC. 

The fundamental behavioural change for allergic conjunctivitis is avoidance of the offending antigen. Topical antihistamines, mast cell stabilizers, nonsteroidal anti-inflammatory medicines (NSAIDs), and corticosteroids can all be used to treat allergic conjunctivitis. Common drugs include antihistamines, which block the effects of histamine and relieve itching and redness. Mast cell stabilizers prevent the release of allergic substances and effectively control symptoms. Nonsteroidal anti-inflammatory medications (NSAIDs) help alleviate pain and inflammation. Corticosteroids are potent anti-inflammatory drugs, but their use is typically limited to severe cases due to potential side effects. Combination medications may include a mix of antihistamines and mast cell stabilizers. It's necessary to consult a healthcare professional to determine the most suitable treatment option.

FutureWise Market Research has published a report that provides an insightful analysis of allergic conjunctivitis drug market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the allergic conjunctivitis drug market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
  • Accolade Pharmaceuticals LLC
  • Aldeyra Therapeutics Inc
  • AlleCures Inc
  • Allergan Plc
  • Clevexel Pharma SAS
  • Griffin Discoveries BV
  • Ocular Therapeutix Inc
  • Ohr Pharmaceutical Inc
  • Portola Pharmaceuticals Inc
  • Re-Pharm Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Allergic Conjunctivitis Drug Market:

In April 2023- Aldeyra Therapeutics, Inc. announced that enrolment in the Phase 3 INVIGORATE-2 clinical trial of topical ocular reproxalap, a first-in-class investigational novel medication candidate for the treatment of allergic conjunctivitis, has been completed.

The rising prevalence of allergic conjunctivitis is expected to drive growth in the worldwide market over the forecast period. In the last few decades, the identification of allergic disorders has increased, and allergic conjunctivitis has developed as a significant concern expected to cause severe ocular surface disease. Itching, watering, and redness are common complaints among patients. Allergic conjunctivitis affects up to 42% of the population, yet only a tiny percentage of those affected seek medical attention. Itching is the most common symptom of allergic conjunctivitis, and it is treated with topical antihistamines and mast cell inhibitors. Moreover, companies are investing in the development of novel drug formulations, including eye drops and other ophthalmic medications, to effectively manage allergic conjunctivitis symptoms. The aim is to provide improved treatment options that offer faster relief, longer duration of action, and reduced side effects. Major market players in the pharmaceutical industry are actively involved in the development of innovative treatments for allergic conjunctivitis. This focus on research and development is expected to drive the growth of the global allergic conjunctivitis market during the forecast period. R&D activities are pivotal in driving innovation and advancing the understanding of allergic conjunctivitis. Market players focus on developing novel drug formulations, exploring new therapeutic approaches, and improving drug delivery systems. R&D efforts aim to address the limitations of existing treatments and provide more targeted and efficient solutions for allergic conjunctivitis management. However, some common side effects of antihistamine and mast cell stabilizer eye drops may include a mild stinging or burning sensation upon application, temporary blurred vision, or dryness of the eyes. Prolonged use or high doses of corticosteroids can increase the risk of elevated intraocular pressure (glaucoma), cataract formation, and potential for infection. These medications are typically used for short periods and under close supervision. It's important to note that the occurrence of side effects can vary among individuals. The aforementioned factors are expected to limit the market growth.

By Product Type

  • CPC-888
  • CVXL-0074
  • ADX-102
  • AGN-229666
  • Dexamethasone Acetate SR
  • Others

By Application

  • Hospital
  • Clinic
  • Research Center
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. due to factors including the widespread consumer awareness of conjunctivitis in the area and the ease with which efficient treatment products are available. The majority of the population (15–40%) in the nation suffers from conjunctivitis, which is most common in the spring and summer. According to the NCBI article from January 2021, seasonal or perennial allergic conjunctivitis accounts for more than 95% of cases of ocular allergies in the country. It is also the most common kind of allergic conjunctivitis. As seen in both sexes, 15% and 40% of the population are affected. The high frequency of conjunctivitis in the United States is anticipated to increase demand for effective treatments, fuelling the market's expansion throughout the forecast period. 
  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants
  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth
  •  To provide with an exhaustive analysis on the Allergic Conjunctivitis Drug Market By Product Type, By Application and By Region
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization services offered are free of charge with purchase of any license of the report.
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data From Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Allergic Conjunctivitis Drug Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Allergic Conjunctivitis Drug Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Allergic Conjunctivitis Drug Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. CPC-888
        2. CVXL-0074
        3. ADX-102
        4. AGN-229666
        5. Dexamethasone Acetate SR
        6. Others

  • 8.   Global Allergic Conjunctivitis Drug Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital
        2. Clinic
        3. Research Center
        4. Others

  • 9.   North America Allergic Conjunctivitis Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) along with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Europe Allergic Conjunctivitis Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9.Rest of Western Europe
             3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 11.   Asia Pacific Allergic Conjunctivitis Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) - along with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 12.   Middle East and Africa Allergic Conjunctivitis Drug Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) along with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 13.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 14.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •        1. Accolade Pharmaceuticals LLC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aldeyra Therapeutics Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AlleCures Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Allergan Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Clevexel Pharma SAS
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Griffin Discoveries BV
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ocular Therapeutix Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Ohr Pharmaceutical Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Portola Pharmaceuticals Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Re-Pharm Ltd
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 15.  FutureWise SME Key Takeaway Points for Client

    •     


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11